Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Weekly Docetaxel, Vinorelbine, and Herceptin in the First-Line Treatment of Patients With Metastatic Breast Cancer and Overexpression of Her-2

NCT00193089 is registered in ClinicalTrials.gov with SCRI Development Innovations, LLC as lead sponsor.

NCT NCT00193089
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00193089 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Weekly Docetaxel, Vinorelbine, and Herceptin in the First-Line Treatment of Patients With Metastatic Breast Cancer and Overexpression of Her-2
Lead sponsor
SCRI Development Innovations, LLC
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2001
Completion date
September 30, 2009
Enrollment
60 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer